Press Release | Newsroom | Medtronic | Bayer’s New CONTOUR® NEXT LINK Blood Glucose Meter Now Available with Compatible Medtronic Insulin Pumps

Press Release

Printer Friendly Version View printer-friendly version
Download PDF Download PDF
<< Back
Bayer’s New CONTOUR® NEXT LINK Blood Glucose Meter Now Available with Compatible Medtronic Insulin Pumps

Medtronic, Inc. (NYSE: MDT) and Bayer HealthCare today announced that Bayer’s CONTOUR® NEXT LINK, a new blood glucose meter, is now available in the U.S. with Medtronic’s compatible integrated diabetes management systems.

Bayer’s new meter provides exceptional accuracy utilizing high-performance CONTOUR® NEXT test strips, helping optimize insulin delivery through wireless communication with the MiniMed® Paradigm™ REAL-Time Revel™ insulin pump and the MiniMed Paradigm Real Time Insulin pump. People with diabetes can have greater confidence that seamless integration with Medtronic’s Bolus Wizard® makes bolus calculations quick and easy, eliminating inaccuracies due to manual entry errors.

Bayer’s CONTOUR® NEXT LINK utilizes the new, high-accuracy CONTOUR® NEXT test strips that deliver exceptional accuracy for close-to-professional lab results that people with diabetes can count on, especially in the low glucose range (<75 mg/dL). 

Other features of CONTOUR® NEXT LINK include:

  • Enables fast and easy bolus dosing and continuous glucose monitoring calibration
  • Pass-through feature allows for easy downloading to Medtronic’s convenient online CareLINK® software, replacing the CareLINK® USB device
  • Bayer’s No Coding™ technology makes testing easy by automatically setting the correct code each time a test strip is inserted
  • Easy-to-read display with large, clear numbers
  • Fast 5-second countdown and small 0.6 μL blood sample
  • Optional pre- and post-meal markers with audible reminders

Starting today, new Medtronic customers will receive CONTOUR® NEXT LINK with any new pump order. Existing customers will be contacted by Medtronic and provided with new meters over time, beginning in January of 2013.

CONTOUR® NEXT LINK is also compatible with the Guardian® REAL-Time continuous glucose monitoring system.

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 17.2 billion (2011), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (December 31, 2011) and is represented in more than 100 countries. Find more information at www.bayerhealthcare.com.

About the Diabetes Business at Medtronic
The Diabetes business at Medtronic (www.medtronicdiabetes.com and www.medtronic-diabetes.co.uk) is the world leader in diabetes management.  The product line of the Diabetes business includes insulin pump therapy, continuous glucose monitoring systems, related disposable products and diabetes management software.

About Medtronic
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology - alleviating pain, restoring health and extending life for millions of people around the world.

Bayer Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
 
Medtronic Forward-Looking Statements
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

-end-

Medtronic Media Contacts:
Amanda Sheldon, Public Relations, 818-576-4826
Jeff Warren, Investor Relations, 763-505-2696
Susan Yarin, Bayer HealthCare, 914-366-1738
X